Mediolanum International Funds Ltd Sells 5,501 Shares of United Therapeutics Corporation $UTHR

Mediolanum International Funds Ltd trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 85.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 959 shares of the biotechnology company’s stock after selling 5,501 shares during the period. Mediolanum International Funds Ltd’s holdings in United Therapeutics were worth $564,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Norges Bank bought a new stake in shares of United Therapeutics in the 4th quarter worth $293,418,000. Avoro Capital Advisors LLC raised its stake in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Finally, Baillie Gifford & Co. bought a new position in shares of United Therapeutics during the fourth quarter valued at $157,390,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $535.83 on Wednesday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a fifty day moving average of $550.65 and a 200 day moving average of $530.90. The stock has a market cap of $22.75 billion, a PE ratio of 19.78, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.63 earnings per share. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $568.83, for a total value of $5,688,300.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,737,235.08. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 535,379 shares of company stock valued at $299,468,343. 8.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Bank of America decreased their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.